Literatur
- 1
Benson J R, Jatoi I, Keisch M et al.
Early breast cancer.
Lancet.
2009;
373
1463-1479
- 2
Early Breast Cancer Trialists’ Collaborative Group .
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence
and 15-year survival: An overview of the randomised trials.
Lancet.
2005;
365
1687-1717
- 3
Alvarez R H, Valero V, Hortobagyi G N.
Emerging Targeted Therapies for Breast Cancer.
J Clin Oncol.
2010;
28
3366-3379
- 4 Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database
Syst Rev CD003474 2005
- 5
Perou C, Sørlie T, Eisen M et al.
Molecular portraits of human breast tumours.
Nature.
2000;
406
747-752
- 6
Sørlie T, Perou C M, Tibshirani R et al.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical
implications.
Proc Natl Acad Sci U S A.
2001;
98
10869-10874
- 7
van’t Veer L J, Dai H, van de Vijver M J et al.
Gene expression profiling predicts clinical outcome of breast cancer.
Nature.
2002;
415
530-536
- 8
Paik S, Shak S, Tang G et al.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast
cancer.
N Engl J Med.
2004;
351
2817-2826
- 9
Paik S, Tang G, Shak S et al.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen
receptor-positive breast cancer.
J Clin Oncol.
2006;
24
3726-3734
- 10
Wirapati P, Sotiriou C, Kunkel S et al.
Meta-analysis of gene-expression profiles in breast cancer: Toward a unified understanding
of breast cancer sub-typing and prognosis signatures.
Breast Cancer Res.
2008;
10
R65
- 11
Goldhirsch A, Ingle J N, Gelber R D et al.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus
on the Primary Therapy of Early Breast Cancer 2009.
Ann Oncol.
2009;
20
1319-1329
- 12
Beslija S, Bonneterre J, Burstein H J et al.
Third consensus on medical treatment of metastatic breast cancer.
Ann Oncol.
2009;
20
1771-1785
- 13
Franco A, Col N, Chlebowski R.
Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic
breast cancer: A meta-analysis.
J Clin Oncol.
2004;
22
abstr 539
11
- 14
Santinelli A, Pisa E, Stramazzotti D et al.
HER-2 status discrepancy between primary breast cancer and metastatic sites: Impact
on target therapy.
Int J Cancer.
2008;
122
999-1004
- 15
Slamon D J, Leyland-Jones B, Shak S et al.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast
cancer that overexpresses HER2.
N Engl J Med.
2001;
344
783-792
- 16
Marty M, Cognetti F, Maraninchi D et al.
Randomized phase II trial of the efficacy and safety of trastuzumab combined with
docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic
breast cancer administered as first-line treatment: The M77001 Study Group.
J Clin Oncol.
2005;
23
4265-4274
- 17
Wilcken N, Dear R.
Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported
2000–2007.
Eur J Cancer.
2008;
44
2218-2225
- 18
Perez E A.
Breast Cancer Management: Opportunities and barriers to an individualized approach.
Oncologist.
2011;
16
20-22
- 19
Brennan D J, Kelly C, Rexhepaj E et al.
Contribution of DNA and tissue microarray technology to the identification and validation
of biomarkers and personalised medicine in breast cancer.
Cancer Genomics Proteomics.
2007;
4
121-134
Prof. Dr. med. A. Schneeweiss
Sektion Gynäkologische Onkologie · Nationales Centrum für Tumorerkrankungen (NCT)
· Universitäts-Klinikum
Im Neuenheimer Feld
69120 Heidelberg
Email: andreas.schneeweiss@med.uni-heidelberg.de
